# US 2008/0187512 A1 · Treatment for spinal muscular atrophy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0187512 A1
- Document ID: US20080187512A1
- Status: Published application
- Kind: A1
- Application number: 11/703,810
- Filed: 2007-02-07
- Published: 2008-08-07
- Earliest claimed: 2007-02-07
- Assignees: Academia Sinica
- Inventors: Hung Li
- Web page: https://patentgrep.com/patent/US20080187512A1

## CPC

- A61K 31/70: Carbohydrates; Sugars; Derivatives thereof (sorbitol A61K31/047)
- A61K 38/1709: {from mammals}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- G01N 33/5041: {involving analysis of members of signalling pathways}
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- G01N 2500/10: involving cells
- G01N 2800/2878: Muscular dystrophy
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Compositions for treatment of spinal muscular atrophy (SMA) and methods for use thereof to treat SMA and other conditions of SMN-deficiency; novel drug development targets for SMA therapies, and methods of use thereof to screen for candidate therapeutic and diagnostic agents.

## Claims

### Claim 1

A method for treating spinal muscular atrophy (SMA) or other SMN-deficiency in a subject, the method comprising administering to said subject a therapeutically effective amount of a pharmaceutically acceptable activator of Stat5.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the Stat5 activator is chosen from: interferon-alpha (IFNα); interleukins IL-2, IL-3, IL-5, IL-6, IL-7, and IL-15; granulocyte/macrophage-colony stimulating factor (GM-CSF); growth hormone (GH); epidermal growth factor (EGF); erythropoietin (EPO); prolactin (PRL); thrombopoietin (TRP); trichostatin A (TSA); aclarubicin; sodium vanadate; and combinations thereof.

### Claim 3

A method for treating SMA or other SMN-deficiency in a subject, the method comprising administering to said subject a recombinant genetic vector comprising at least one copy of a host-expressible gene encoding Stat5A.

### Claim 4 (depends on 3)

The method according to claim 3, wherein the Stat5A is a constitutively activated Stat5A.

### Claim 5 (depends on 4)

The method according to claim 4, wherein the constitutively activated Stat5A is a Stat5A comprising (1) Phe710 and at least one of Arg298 or Gly150, or (2) His642, according to the numbering of SEQ ID NO:3.

### Claim 6 (depends on 4)

The method according to claim 4, wherein the constitutively activated Stat5A is a Stat5A comprising Phe710 and Arg298, according to the numbering of SEQ ID NO:3.

### Claim 7 (depends on 4)

The method according to claim 4, wherein the Stat5 is Stat5A1*6.

### Claim 8 (depends on 3)

The method according to claim 3, wherein the vector is a viral vector

### Claim 9 (depends on 8)

The method according to claim 8 wherein the viral vector is an adenoviral, adeno-associated viral, herpes viral, or lentiviral vector.

### Claim 10

A method for identifying a candidate compound for treatment of SMA comprising
(A) providing (1) a mammalian cell that is Stat5(+) and that contains an expressible, Stat5-activatable target nucleic acid whose promoter contains at least one Gamma-Activated Sequence (GAS) element and at least one CTCNNNTAA motif, and (2) at least one test compound;
(B) contacting the cell with the test compound (1) under conditions in which the test compound can activate Stat5 or (2) under conditions in which the test compound can increase expression of Stat5 and conditions in which Stat5 can be activated; and
(C) detecting the level of expression of the target nucleic acid or of a phenotypic effect resulting from expression thereof,
whereby detection of an increased level of expression of the target nucleic acid or an increase in the phenotypic effect identifies the test compound as a candidate compound for SMA treatment.

### Claim 11 (depends on 10)

The method according to claim 10, wherein the mammalian cell is a Stat5(+)/SMN2(+) cell and the detection involves assaying the level of SMN2 transcripts, the level of SMN or SMNΔ7 protein, or the occurrence of nuclear gems in the cell nucleus.

### Claim 12 (depends on 10)

The method according to claim 10, wherein the GAS element has a sequence of any one of ttcnnn(n)gaa, ttcnnn(n)gag, or ttcnnn(n)gta.

### Claim 13 (depends on 12)

The method according to claim 12, wherein the GAS element has a sequence of any one of ttcynrgaa, ttcynrgag, or ttcynrgta.

### Claim 14 (depends on 13)

The method according to claim 13, wherein the ynr segment of the GAS element has a sequence of any one of cng or cna.

### Claim 15 (depends on 14)

The method according to claim 14, wherein the GAS element has a sequence of any one of ttccaggag or ttcctagta.

### Claim 16

A nucleobase probe containing a base sequence of CTCNNNTAA or the complement thereof, or the RNA base equivalent to either of these.

### Claim 17 (depends on 16)

The nucleobase probe according to claim 16, wherein the probe comprises DNA or a nucleic acid analog.

### Claim 18

A method for screening to identify a candidate Stat5-regulated gene, the method comprising:
(A) providing a nucleobase probe containing a base sequence of CTCNNNTAA or the complement thereof, or the RNA base equivalent to either of these.
(B) contacting a gene-containing cell, cell fragment, or polynucleotide preparation with the probe under conditions in which the probe can hybridize specifically to a sequence complementary to the base sequence of (A) to form hybrids, and removing non-specifically hybridized probes therefrom to leave remaining hybrids, and
(C) detecting remaining hybrids and determining that the target sequence to which the base sequence of (A) has bound is located in a gene promoter region,
whereby detection of a remaining hybrid identifies the gene member thereof, or the gene from which the promoter was obtained, as a candidate Stat5-regulated gene.

### Claim 19

A method for screening to identify a candidate Stat5 protein comprising:
(A) providing a nucleobase probe containing a base sequence of CTCNNNTAA or the complement thereof;
(B) contacting the probe with a polypeptide having the amino acid sequence of Stat(5) or an amino acid sequence at least 70% identical thereto, under conditions in which the polypeptide can specifically bind to the base sequence of (A), to form a complex, and removing non-specifically bound probes therefrom to leave remaining complexes, and
(C) detecting remaining complexes,
whereby detection of a remaining complex identifies the polypeptide member thereof as a candidate Stat5 protein.

### Claim 20

A method for treating SMA or other SMN-deficiency in a subject, the method comprising administering to said subject a recombinant genetic vector comprising at least one copy of a host-expressible gene encoding Stat5A and comprising at least one copy of a Stathmin inhibitor.

### Claim 21 (depends on 20)

The method according to claim 20, wherein the Stat5A is a constitutively activated Stat5A.

### Claim 22 (depends on 21)

The method according to claim 21, wherein the constitutively activated Stat5A is a Stat5A comprising (1) Phe710 and at least one of Arg298 or Gly150, or (2) His642, according to the numbering of SEQ ID NO:3.

### Claim 23 (depends on 21)

The method according to claim 21, wherein the constitutively activated Stat5A is a Stat5A comprising Phe710 and Arg298, according to the numbering of SEQ ID NO:3.

### Claim 24 (depends on 21)

The method according to claim 21, wherein the Stat5 is Stat5A1*6.

### Claim 25 (depends on 20)

The method according to claim 20, wherein the inhibitor in a Stathmin expression inhibitor.

### Claim 26 (depends on 20)

The method according to claim 20, wherein the copy is a copy of a host-expressible Stathmin inhibitor.

### Claim 27 (depends on 26)

The method according to claim 26, wherein the copy is a copy of a host-expressible Stathmin expression inhibitor.

### Claim 28 (depends on 20)

The method according to claim 20, wherein the inhibitor is or encodes an RNAi nucleic acid.

### Claim 29 (depends on 28)

The method according to claim 28, w the RNAi nucleic acid is a shRNA.

### Claim 30 (depends on 28)

The method according to claim 28, wherein the target sequence of the antisense or RNAi nucleic acid is CGTTTGCGAGAGAAGGATA (nt728-746 of SEQ ID NO:10).

### Claim 31 (depends on 20)

The method according to claim 20, wherein the vector is a viral vector

### Claim 32 (depends on 31)

The method according to claim 31, wherein the viral vector is an adenoviral, adeno-associated viral, herpes viral, or lentiviral vector.
